News
-
Kindeva Drug Delivery has announced that it will install a second LGWP propellant MDI manufacturing line at its facility in Loughborough, UK. The company’s first LGWP line at Loughborough is expected to be completed by the… Read more . . .
-
Gossamer Bio and Chiesi Farmaceutici have partnered to develop and commercialize Gossamer’s seralutinib inhalation powder for the treatment of pulmonary hypertension, the companies announced. Chiesi, which will get 50% of US commercial profit and ex-US rights… Read more . . .
-
According to Iconovo, the Chinese Patent Office has said it will approve the company’s application for a patent covering its ICOres reservoir-based dry powder inhaler platform that will provide protection until 2040. The ICOres platform… Read more . . .
-
MannKind Corporation announced that its MNKD-101 clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung infections has been granted Fast Track designation by the FDA. MNKD-101 had already received orphan drug and qualified infectious… Read more . . .
-
Device and component maker H&T Presspart and CDMO Bespak, which recently spun out from Recipharm, have announced that they will collaborate on projects related to low global warming potential (LGWP) propellants. According to the companies,… Read more . . .
-
ARS Pharmaceuticals announced has submitted its Day 180 response regarding the company’s MAA for Neffy epinephrine nasal spray to the EMA’s Committee for Medicinal Products for Human Use (CHMP) and expects an opinion on the… Read more . . .
-
MannKind Corporation says that it will move ahead with a Phase 1 SAD/MAD study of MNKD-201 dry powder nintedanib for inhalation, which the company is developing for the treatment of fibrotic diseases of the lung, including… Read more . . .
-
MannKind Corporation announced that the FDA has cleared the company’s IND for the ICoN-1 Phase 3 study of MNKD-101 clofazimine inhalation suspension in patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). The… Read more . . .
-
Nebu-Flow announced that it has closed a $5.9 million funding round led by venture capital firm SCVC that will support continued development of the company’s surface acoustic wave (SAW) nebulization technology. In 2022, the University of… Read more . . .
-
According to ENA Respiratory, the FDA has cleared the company’s IND for a Phase 1b study of a dry powder formulation of INNA-051, a TLR2/6 agonist, which the company has been developing as a pan-viral… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK